Catalog No.: PC-25071Not For Human Use, Lab Use Only.
Lotixparib (DM5167) is a potent, selective PARP1 inhibitor with IC50 of 0.41 nM, displays >300-fold preference for PARP1 over PARP2 in in vitro enzymatic and DNA capture assays.
Lotixparib (DM5167) is a potent, selective PARP1 inhibitor with IC50 of 0.41 nM, displays >300-fold preference for PARP1 over PARP2 in in vitro enzymatic and DNA capture assays.
DM5167 shows higher selectivity than AZD5305 in the enzymatic assay.
DM5167 efficiently reduces growth of triple-negative breast cancers.
DM5167 achieved a 45.8% tumor growth inhibition at a dose of 50 mg/kg in orthotopic xenograft model using triple-negative breast cancer cell lines.
1. Patent WO2021086077 A1.
2. Kim JW, et al. Pharm Res. 2025 Oct 22. doi: 10.1007/s11095-025-03939-8.
3. Sujin Nam, et al. Cancer Res (2023) 83 (7_Supplement): 509.
